Please login to the form below

Not currently logged in
Email:
Password:

eosinophilic

This page shows the latest eosinophilic news and features for those working in and with pharma, biotech and healthcare.

FDA grants priority review for AZ, Amgen’s tezepelumab for asthma

FDA grants priority review for AZ, Amgen’s tezepelumab for asthma

Tezepelumab is a potentially first-in-class thymic stromal lymphopoietin (TSLP) targeting antibody – TLSP is a key epithelial cytokine that initiates an overactive immune response to allergic, eosinophilic and other types ... In September 2018,

Latest news

More from news
Approximately 2 fully matching, plus 45 partially matching documents found.

Latest Intelligence

  • Exploring the potential of eosinophils Exploring the potential of eosinophils

    Having too many eosinophils in certain tissues is an important contributor to a range of conditions including severe eosinophilic asthma (SEA), nasal polyps, eosinophilic oesophagitis and rarer, systemic diseases such as ... Interestingly, Howarth

  • Gut instincts lead Takeda to GI pipeline success Gut instincts lead Takeda to GI pipeline success

    It also plans to achieve the first FDA therapy approval to treat eosinophilic oesophagitis, a chronic, allergic condition with little current respite.

  • GSK forges ahead with its dynamic COPD and asthma portfolio GSK forges ahead with its dynamic COPD and asthma portfolio

    mepolizumab to treat COPD exacerbations with eosinophilic inflammation. ... You would imagine coronavirus would be one of those threats.”. GSK is trialling its biologic anti IL-5 drug mepolizumab, licensed for severe asthma, in eosinophilic COPD with a

  • The long and winding road to asthma breakthroughs The long and winding road to asthma breakthroughs

    GSK is also anticipating data in hyper-eosinophilic syndrome and nasal polyposis which could lead to commercial approvals in both by the end of 2020. ... Severe eosinophilic asthma (SEA) impacts between 5-10% of the population but they, and other severe

  • Pharma deals in August 2015 Pharma deals in August 2015

    Baxalta aside, it has been a busy year for Shire which in February acquired the company Meritage bringing in a phase III ready oral budesonide solution for eosinophilic oesophagitis [an orphan

More from intelligence
Approximately 0 fully matching, plus 7 partially matching documents found.

Latest from PMHub

  • Article

    Inhale, Exhale: The struggle of living with Severe Asthma and Severe Eosinophilic Asthma. ... Head of “Living With”, Mariel Metcalfe, discusses the nature of severe asthma and severe eosinophilic asthma, and some key findings from recent studies

  • Research Partnership

    Inhale, Exhale: The struggle of living with Severe Asthma and Severe Eosinophilic Asthma.

More from PMHub
Approximately 1 fully matching, plus 1 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
SEVEN STONES

Seven Stones is a creative, independent healthcare communications agency of movers and thinkers. We've been doing health differently since 1991....

Latest intelligence

Diversity in clinical trials: looking back at our 2021 blogs
In this blog, we look back at the Innovative Trials' Equality & Diversity (E&D) committee blogs across 2021...
What does the future hold for Light-chain Amyloidosis?
Recent advances in the understanding and treatment are reforming pharma’s approach to the management of this rare disease. With a new standard of care rapidly developing, what does the landscape...
Webinar:
Securing a future for telehealth with immersive market research insights...